Our data suggest that an aberrant increase in PLD expression in cancer cells will lead to increased PA levels and subsequent mTOR activation48, 49, 50 only if in addition the expression of LKB1 is reduced, because PA-mediated LKB1/AMPK activation normally counteracts mTOR activity. The gene discussed is STK11; the disease is cancer.